## Drug Monograph

Drug/Drug Class: **Lucentis® (Ranibizumab) Recombinant Humanized Monoclonal Antibody**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage LLC
☒ **New Criteria** ☐ **Revision of Existing Criteria**

## Executive Summary

| | |
|---|---|
| **Purpose:** | The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use. |
| **Dosage Forms:** | Each vial of Lucentis® 0.3mg contains 6 mg/ml Ranibizumab,10% α,α-trehalose dihydrate, 0.01% polysorbate 20, and 10 mM histidine HCL |
| **Manufacturer:** | GENENTECH, INC<br>South San Francisco, CA USA 94080-4990 |
| **Indications:** | To provide treatment to patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), or Macular Edema Following Retinal Vein Occlusion (RVO). |
| **Costs:** | $ 23,634.00 per vial of Lucentis Maximum Allowable Cost |
| **Summary of Findings:** | MO HealthNet Division recommends Open Access status for this product. |
| **Status Recommendation:** | ☐ Prior Authorization (PA) Required ☒ Open Access<br>☐ Clinical Edit ☐ PDL |
| **Type of PA Criteria:** | ☐ Increased Risk of ADE ☐ Preferred Agent<br>☐ Appropriate Indications ☒ No PA Required |

Prepared By: Ami Patel, Pharm. D. Candidate
Date: October 26th, 2012